An analytics approach to designing combination chemotherapy regimens for cancer

Management Science

Volumn 62, Issue 5, 2016, Pages 1511-1531

  Bertsimas, Dimitris ^a   O'Hair, Allison ^b   Relyea, Stephen ^c   Silberholz, John ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Healthcare; Integer; Programming; Simulation; Statistics; Treatment

Indexed keywords

ARTIFICIAL INTELLIGENCE; CHEMOTHERAPY; DISEASES; FORECASTING; HEALTH CARE; INTEGER PROGRAMMING; LEARNING SYSTEMS; MATHEMATICAL PROGRAMMING; QUALITY CONTROL; STATISTICS; TOXICITY;

CLINICAL PRACTICES; COMBINATION CHEMOTHERAPY; CURRENT PRACTICES; INTEGER; OVERALL SURVIVAL; PRIMARY OBJECTIVE; SIMULATION; TREATMENT;

MEDICAL APPLICATIONS;

EID: 84968779588     PISSN: 00251909     EISSN: 15265501     Source Type: Journal    
DOI: 10.1287/mnsc.2015.2363     Document Type: Article

References (56)

1. Ajani J, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/ infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J. Clinical Oncology 28(9):1547-1553.
2. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick, F, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697.
3. Breiman L (2001) Random forests. Machine Learn. 45(1):5-32.
4. Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur. J. Cancer 32(7):1135-1141.
5. Burke H (1997) Artificial neural networks improve the accuracy of cancer survival prediction. Cancer 79(4):857-862.
6. Canty A, Ripley B (2014) boot: Bootstrap R 4S-Plus5 Functions. Package version 1.3-13.
7. Chao Y, Li CP, Chao TY, Su WC, Hsieh RK, Wu MF, Yeh KH, Kao WY, Chen LT, Cheng AL (2006) An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. British J. Cancer 95(2):159-163.
8. Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Rev. 58(3):621-681.
9. Davison AC, Hinkley DV (1997) Bootstrap Methods and Their Applications (Cambridge University Press, Cambridge, UK).
10. Dearden R, Friedman N, Russell S (1998) Bayesian Q-learning. AAAI-98 Proc. (AAAI Press, Palo Alto, CA), 761-768.
11. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. J. Amer. Medical Assoc. 292(4):470-484.
12. Delen D, Walker G, Kadam A (2005) Predicting breast cancer survivability: A comparison of three data mining methods. Artificial Intelligence Medicine 34(2):113-127.
13. De Ridder F (2005) Predicting the outcome of phase III trials using phase II data: A case study of clinical trial simulation in late stage drug development. Basic Clinical Pharmacology Toxicology 96(3):235-241.
14. Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacology Therapeutics 107(2):155-176.
15. Frazier PI, Powell WB, Dayanik S (2008) A knowledge-gradient policy for sequential information collection. SIAM J. Control Optim. 47(5):2410-2439.
16. Friedman J, Hastie T, Tibshirani R (2010a) Regularization paths for generalized linear models via coordinate descent. J. Statist. Software 33(1):1-22.
17. Friedman LM, Furberg CD, DeMets DL (2010b) Fundamentals of Clinical Trials, Vol. 4 (Springer, New York).
18. Golan DE, Tashjian AH Jr, Armstrong EJ, Armstrong AW, eds. (2008) Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 2nd ed. (Lippincott, Williams and Wilkins, Philadelphia).
19. Hastie T, Tibshirani R, Friedman J (2009) The Elements of Statistical Learning, 2nd ed. (Springer, New York).
20. Hoerl AE, Kennard RW (1970) Ridge regression: Biased estimation for nonorthogonal problems. Technometrics 12(1):55-67.
21. Hsu C, Shen Y-C, Cheng C-C, Cheng AL, Hu FC, Yeh KH (2012) Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression. Gastric Cancer 15(3): 265-280.
22. Hsu C-W, Chang C-C, Lin C-J (2003) A practical guide to support vector classification. Technical report, Department of Computer Science, National Taiwan University. Accessed June 4, 2013, http://www.csie.ntu.edu.tw/~cjlin/papers/guide/guide.pdf.
23. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, et al. (2011) Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J. Clinical Oncology 29(25):3457-3465.
24. Iwase H, Shimada M, Tsuzuki T, Ina K, Sugihara M, Haruta J, Shinoda M, Kumada T, Goto H (2011) A phase II multicenter study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. Oncology 80(1-2): 76-83.
25. Jefferson M, Pendleton N, Lucas S, Horan MA (1997) Comparison of a genetic algorithm neural network with logistic regression for predicting outcome after surgery for patients with nonsmall cell lung carcinoma. Cancer 79(7):1338-1342.
26. Kang Y-K, Kang W-K, Shin D-B, Chen J, Xiong J, Wang J, Lichinitser M, et al. (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann. Oncology 20(4):666-673.
27. Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. MacLeod CM, ed. Evaluation of Chemotherapeutic Agents (Columbia University Press, New York), 191-205.
28. Kleiman M, Sagi Y, Bloch N, Agur Z (2009) Use of virtual patient populations for rescuing discontinued drug candidates and for reducing the number of patients in clinical trials. Alternatives Lab Animals 37(Supplement 1):39-45.
29. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, et al. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet 9(3):215-221.
30. Lee KH, Hyun MS, Kim H-K, Jin HM, Yang J, Song HS, Do YR, et al. (2009) Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res. Treatment 41(1):12-18.
31. Lee Y-J, Mangasarian OL, Wolberg WH (2003) Survival-time classification of breast cancer patients. Comput. Optim. Appl. 25(1):151-166.
32. Liaw A, Wiener M (2002) Classification and regression by random- Forest. R News 2(3):18-22. http://CRAN.R-project.org/doc/ Rnews/.
33. Lutz MP, Wilke H, Wagener DJT, Vanhoefer U, Jeziorski K, Hegewisch- Becker S, Balleisen L, et al. (2007) Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: Randomized phase II trial 40,953 of the European organisation for research and treatment of cancer gastrointestinal group and the arbeitsgemeinschaft internistische onkologie. J. Clinical Oncology 25(18):2580-2585.
34. Meyer D, Dimitriadou E, Hornik K, Weingessel A, Leisch F, Chang CC, Lin CC (2012) e1071: Misc Functions of the Department of Statistics, Probability Theory Group (formerly: E1071), TU Wien. R package version 1.6-1. http://CRAN.R -project.org/package=e1071.
35. National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3 .pdf.
36. NCCN (National Comprehensive Cancer Network) (2014) NCCN Guidelines for Gastric Cancer, Version 1.2014 (NCCN, Fort Washington, PA). Accessed October 15, 2014, http://www.nccn.org/ professionals/physician-gls/pdf/gastric.pdf.
37. Ohno-Machado L (2001) Modeling medical prognosis: Survival analysis techniques. J. Biomedical Informatics 34(6):428-439.
38. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Amer. J. Clinical Oncology 5(6):649-656.
39. Overmoyer B (2003) Combination chemotherapy for metastatic breast cancer: Reaching for the cure. J. Clinical Oncology 21(4): 580-582.
40. Page R, Takimoto C (2002) Principles of chemotherapy. Pazdur R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach: Medical, Surgical and Radiation Oncology (PRR Inc., Melville, NY), 21-38.
41. Phan J, Moffitt R, Stokes T, Liu J, Young AN, Nie S, Wang MD (2009) Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotech. 27(6):350-358.
42. Pratt WB (1994) The Anticancer Drugs (Oxford University Press, New York).
43. R Development Core Team (2011) R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available at http://www.R -project.org/.
44. Roth AD (2003) Chemotherapy in gastric cancer: A never ending saga. Ann. Oncology 14(2):175-177.
45. Sertkaya A, Birkenbach A, Berlind A, Eyraud J (2014) Examination of clinical trial costs and barriers for drug development. Technical Report HHSP23337007T, U.S. Department of Health and Human Services, Washington, DC.
46. Thompson S, Higgins J (2002) How should meta-regression analyses be undertaken and interpreted? Statist. Medicine 21(11): 1559-1573.
47. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: A randomized phase II study. J. Clinical Oncology 23(3): 494-501.
48. Tibshirani RJ (1996) Regression shrinkage and selection via the Lasso. J. Roy. Statist. Soc. Ser. B 58(1):267-288.
49. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J. Clinicians 65(2):87-108.
50. van't Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187):564-570.
51. Wagner A (2006) Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J. Clinical Oncology 24(18):2903-2909.
52. Wong R, Cunningham D (2009) Optimising treatment regimens for the management of advanced gastric cancer. Ann. Oncology 20(4):605-608.
53. World Health Organization (2012) Fact sheets: Cancer. World Health Organization, Geneva.
54. Zhao L, Tian L, Cai T, Claggett B, Wei LJ (2013) Effectively selecting a target population for a future comparative study. J. Amer. Statist. Assoc. 108(502):527-539.
55. Zhao Y, Kosorok MR, Zeng D (2009) Reinforcement learning design for cancer clinical trials. Statist. Med. 28(26):3294-315.
56. Zhao Y, Zeng D, Rush AJ, Kosorok MR (2012) Estimating individualized treatment rules using outcome weighted learning. J. Amer. Statist. Assoc. 107(499):1106-1118.